Category: Coronavirus

Moderna Insider Trading Reports

Moderna (NASDAQ: MRNA) insider trading reports (Form 4)

CEO Stephan Bancel

Key officers and directors: Sell, Sell, Sell!

https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852

Owner Filings Transaction Date Type of Owner
Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer
Zaks Tal Zvi 0001690927 2020-07-27 officer: Chief Medical Officer
Hoge Stephen 0001760669 2020-07-23 officer: President
NABEL ELIZABETH G 0001619929 2020-07-15 director
Tallett Elizabeth E 0001192460 2020-07-01 director
HENDERSON LORI M. 0001221127 2020-06-18 officer: General Counsel and Secretary
Meline David W 0001444612 2020-06-08 officer: Chief Financial Officer
Kim Lorence H. 0001643746 2020-06-02 officer: Chief Financial Officer
AFEYAN NOUBAR 0001222012 2020-05-21 director, 10 percent owner
Flagship Ventures Fund IV, L.P. 0001503559 2020-05-21 10 percent owner
Flagship Ventures Fund IV General Partner LLC 0001508051 2020-05-21 director, 10 percent owner
Flagship Ventures Fund IV-Rx, L.P. 0001590973 2020-05-21 10 percent owner
Andres Juan 0001760670 2020-05-13 officer: See remarks
SAGAN PAUL 0001035440 2020-04-29 director
LANGER ROBERT 0001239757 2020-04-29 director
Nader Francois 0001365343 2020-04-29 director
Horning Sandra 0001638709 2020-04-29 director
Slaoui Moncef 0001712369 2020-04-29 director
Berenson Stephen 0001760671 2020-04-29 director
LEE JENNIFER LING 0001675118 2020-03-09 officer: Chief Accounting Officer

moderna 1

Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer

https://www.fbcoverup.com/docs/library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf

stephane bancel

Sold $30,840,614 in shares in her name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally

https://www.crunchbase.com/organization/bb-biotech-ventures

A Zurcih, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.

http://www.bbbiotechventures.com/en/bb-biotech-ventures/

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,

. . . . . . .

FYI. Ole Stevie boy has been selling his stock out since Nov. 2019.

No buys. All sells.

https://www.fbcoverup.com/docs/library/2020-08-03-Stephane-Bancel-CEO-Moderna-Inc-Form-D-Insider-Trading-Report-SEC-accessed-Aug-03-2020.pdf

bancel stephane

https://yuzuha.substack.com/p/interview-with-moderna-ceo-stephane

. . . . . . .

Moderna’s latest Proxy Statement Form DEF 14A dated Apr. 10, 2020

Massive Wellcome Trust conflict of interest

Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline – GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware,

Moderna’s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust – co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO’S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https://heightzone.com/dr-tal-zaks/

Israeli Tal Zaks – Been only selling his Moderna stock (dumping) since Dec. 2019

This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine.

That is illegal stock manipulation and should land him and his CEO in jail.

C’mon Bill Barr, do your job.

stephane bancel 2

https://www.sec.gov/Archives/edgar/data/1682852/000119312520103908/d915867ddefa14a.htm

Moderna, Inc. (Filer) CIK0001682852 (see all company filings)

IRS No.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38753 | Film No.: 20787049
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

MANAGEMENT

Executives, non-executive directors and director nominee

The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020.

Name Age Position
Executives:
Stéphane Bancel (1) 47 Chief Executive Officer and Director
Juan Andres (1) 55 Chief Technical Operations and Quality Officer
Marcello Damiani 50 Chief Digital and Operational Excellence Officer
Tracey Franklin 40 Chief Human Resources Officer
Lori Henderson, J.D. (1) 58 General Counsel and Corporate Secretary
Stephen Hoge, M.D. (1) 44 President
Lorence Kim, M.D. (1) 45 Chief Financial Officer
Tal Zaks, M.D., Ph.D. (1) 54 Chief Medical Officer
Non-Executive Directors:
Noubar B. Afeyan, Ph.D. (4)(5) 57 Chairman, Director
Stephen Berenson (2)(3) 59 Director
Robert Langer, Sc.D. (4) 71 Director
Elizabeth Nabel, M.D. (4)(5) 68 Director
François Nader, M.D.(5) 63 Director
Israel Ruiz(2)(3) 48 Director
Paul Sagan (2)(3) 61 Director
Moncef Slaoui, Ph.D.(5) 60 Director
Director Nominee:
Sandra Horning, M.D. 71 Director nominee
(1) Executive officer
(2) Member of the Audit Committee
(3) Member of the Compensation and Talent Committee
(4) Member of the Nominating and Corporate Governance Committee
(5) Member of the Product Development Committee

These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING relationships from any involvement in Coronavirus.

https://www.sec.gov/Archives/edgar/data/1682852/000119312518341958/d611137ds1a.htm

moderna edgar search

.

moderna registration

“Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck & Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill & Melinda Gates Foundation. As of September 30, 2018, we have raised over $2.6 billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2 billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.”

moderna prospectus summary

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022435/xslF345X03/form4.xml

non derivatives securities 1

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022138/xslF345X03/form4.xml

non derivatives securities 2

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022102/xslF345X03/form4.xml

non derivatives securities 3

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022102/xslF345X03/form4.xml

non derivatives securities 4

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021763/xslF345X03/form4.xml

non derivatives securities 5

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021495/xslF345X03/form4.xml

non derivatives securities 6

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021332/xslF345X03/form4.xml

non derivative security 7

https://www.sec.gov/Archives/edgar/data/1443340/000089924320018777/xslF345X03/doc4.xml

non derivatives securities 8

https://www.sec.gov/Archives/edgar/data/1443340/000112760220020892/xslF345X03/form4.xml

non derivatives securities 9

https://www.sec.gov/Archives/edgar/data/1443340/000110465920079182/xslF345X03/a4.xml

non derivatives securities 10

https://www.sec.gov/Archives/edgar/data/1443340/000112760220020206/xslF345X03/form4.xml

non derivatives 11

https://www.sec.gov/Archives/edgar/data/1443340/000112760220019726/xslF345X03/form4.xml

non derivatives 12

https://www.sec.gov/Archives/edgar/data/1443340/000112760220018531/xslF345X03/form4.xml

non derivatives 13

The above screen captures are but a few of 120 SELLS from late 2019 to current

See full list of Stephane Bancel Form 4 insider trading reports

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001443340

Here’s a full list of the Moderna Insiders

https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852

moderna insiders

moderna stock exchange

See actual chart entries with hot links above

moderna chart

Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer

https://www.fbcoverup.com/docs/library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf

Sold $30,840,614 in shares in her name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally

https://www.crunchbase.com/organization/bb-biotech-ventures

A Zurich, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.

http://www.bbbiotechventures.com/en/bb-biotech-ventures/

bb biotech

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,

.

Executives

Stéphane Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr. Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies.

Juan Andres joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from

10

Table of Contents

2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.

Marcello Damiani joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr. Damiani held senior roles at bioMérieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr. Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France.

Tracey Franklin has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms. Franklin held positions of increasing responsibility at Merck & Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University.

Lori Henderson, J.D., has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms. Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms. Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College.

Stephen Hoge, M.D., joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.

Lorence Kim, M.D., has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as a Managing Director and co-head of biotechnology investment banking. Dr. Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.

Tal Zaks, M.D., Ph.D., has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.

11

Table of Contents

Non-executive directors

Noubar B. Afeyan, Ph.D., is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.

Stephen Berenson has served as a member of our board of directors since October 2017. Mr. Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr. Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from MIT. We believe that Mr. Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries.

Robert Langer, Sc.D., has served as a member of our board of directors since December 2010. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr. Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors.

Elizabeth Nabel, M.D., has served as a member of our board of directors since December 2015. Dr. Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, since 2010. Dr. Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr. Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr. Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations.

François Nader, M.D., has served as a member of our board of directors since December 2019. Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail

12

Table of Contents

Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr. Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors.

Israel Ruiz has served as a member of our board of directors since February 2017. Mr. Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr. Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr. Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT’s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr. Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master’s degree from the MIT Sloan School of Management. We believe that Mr. Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT.

Paul Sagan has served as a member of our board of directors since June 2018. Mr. Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr. Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr. Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr. Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr. Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields.

Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.

Director nominee

Sandra Horning, M.D., is nominated to serve as a Class II director on our board. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to

13

Table of Contents

2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr. Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience.

. . . . . . .

This financial disclosure is from Moderna’s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018.

It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic… Gates Foundation, DARPA, BARDA, Merck, AstraZeneca (ICI, British government, Queen’s Golden Share) and Moderna’s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust, agent of the Pilgrims Society and the Queen’s Privy Council)

https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm

.

For Those Who Doubt the Plandemic Movie

By Juls Hamrick

I researched some of the “facts” going around claiming to have “debunked” the movie, which are being regurgitated by many who prefer to remain asleep and won’t put the effort in to research things themselves. Here is what I found along with all of my supporting sources.

  1. Dr. Anthony Fauci has worked at the National Institute of Health (NIH) since 1968 and has been a Director with the organization since 1984, “both as a scientist and as the head of the NIAID at the NIH”. A simple Wikipedia search resolved that one.

https://en.wikipedia.org/wiki/Anthony_Fauci

  1. The NIH was one of the institutions funding the original study published in 10/23/2009, which Dr. Mikovits participated in and makes reference to in the Plandemic movie. Dr. Fauci worked at and continues to work at the NIH, one of the primary financial contributors to the study as one of it’s most senior directors, so you can indeed say that Dr. Judy Mikovits was in fact working for Dr. Fauci. I have downloaded the complete original study and saved for you to access here (highlights on page 3 denote Dr. Judy Mikovits’s participation and her employing firm) (highlights on page 6 indicate the institutions which provided the funding for the study):

https://drive.google.com/open?id=1MUVoBB_tL_e-opUws_FQwOfWupbgIj-K

  1. The study was challenged in 2010, when other researches could not replicate their findings and in September 2010, the original team, inclusive of Dr. Judy Mikovits issued an official response supporting their work.

https://drive.google.com/open?id=1duM3FU-Tt60yGkSyqbskEFyrEa37W3nh

  1. After which the original study was partially and then subsequently fully retracted (a very rare move in science). The partial retraction document states that two of the co-authors, Robert Silverman and Das Gupta (whom the original study listed as working for the Department of Cancer Biology) re-analyzed the samples they used and discovered that they had been contaminated. Please refer back to the first link provided herein, for item #1 showing the original study, indicates on the document that it has since been retracted.
  2. That she was arrested and a quote from the prosecuting district attorney, that said the charges were dropped because “there were issues with the witnesses”.

https://www.sciencemag.org/news/2012/06/criminal-charges-dropped-against-chronic-fatigue-syndrome-researcher-judy-mikovits

  1. In September 2012, Dr. Judy Mikovits and a team of other scientists conducted another study replicating the original one and published their findings, ultimately resolving the scientific communities dispute over the original work.

https://twp.duke.edu/sites/twp.duke.edu/files/file-attachments/1441.full_.pdf

https://www.sciencemag.org/news/2012/09/final-study-confirms-virus-not-implicated-chronic-fatigue-syndrome

https://mbio.asm.org/content/3/5/e00266-12

  1. As previously shared in another post, Dr. Fauci does in fact hold a large number of patents related to HIV (as Dr. Judy Mikovits states in the video). He also holds numerous patents related to the Novel Coronavirus.

https://patents.justia.com/search?q=Anthony+Fauci

https://www.wsj.com/articles/SB113383825463714813

Other Interesting and Related Facts:

The Bill and Melinda Gates Foundation has appointed Dr. Anthony Fauci to their Vaccination Action Plan.

https://www.gatesfoundation.org/Media-Center/Press-Releases/2010/12/Global-Health-Leaders-Launch-Decade-of-Vaccines-Collaboration

Bill Gates personally owns a number vaccine related patents (amongst many other interesting and unrelated patents):

https://patents.justia.com/inventor/william-gates

Pirbright, a company funded by The Bill and Melinda Gates Foundation owns European protecting replication of a variant gene of an avian infectious bronchitis virus.

European Patent# 3 172 319 B1 https://data.epo.org/publication-server/pdf-document?pn=3172319&ki=B1&cc=EP&pd=20191120

Here is proof that Pirbright is in fact funded by The Bill and Melinda Gates Foundation

https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2013/11/OPP1098099

Pirbright also a US patent on the Coronavirus (you will need to scroll down quite a bit to see the owner and inventor they really covered every base on this patent.

https://patents.justia.com/patent/10130701

Vanderbilt University owns a large number of Coronavirus vaccine patents:

https://patents.justia.com/patent/7452542

Dr. Anthony Fauci and the Director of Vanderbilt University go back..

Here you see them lobbying together: https://news.vumc.org/tag/anthony-fauci/

Here it mentions how they went to college together:

https://news.vumc.org/tag/anthony-fauci/

Also as previously shared in another post, the polio vaccines the Bill and Melinda Gates Foundation tested on children in the Africa, causing an outbreak of Polio from the vaccine itself and paralysis on the children.

https://thebulletin.org/2018/07/vaccine-causing-polio-in-africa-context-from-an-expert/

Vaccine Wars are British Imperial Wars

conquered common cold

.

Raw audio file: https://aim4truth.org/wp-content/uploads/2020/04/Vaccine-Wars.mp3

charles lieber 1

Exposing Harvard’s Chinese Agent Charles Lieber’s “Virus Transmitters”

Recommended links

EXCLUSIVE: Coronavirus Bioweapon– How China Stole Coronavirus From Canada And Weaponized It (watch here Visualizing The Secret History Of Coronavirus)

Watch the exclusive interview of Bioweapons Expert Dr. Francis Boyle on Coronavirus Biological Warfareblocked by the Deep State

https://greatgameindia.com/coronavirus-bioweapon/

https://greatgameindia.com/dr-francis-boyle-creator-of-bioweapons-act-says-coronavirus-is-biological-warfare-weapon/

REVEALED: U.S. government gave $3.7 million grant to Wuhan lab at center of coronavirus leak scrutiny that was performing experiments on bats from the caves where the disease is believed to have originated

Shocking! US gave $3.7 million to China’s Wuhan lab that conducted coronavirus tests on bats

Dr Rashid Buttar BLASTS Gates, Fauci, EXPOSES Fake Pandemic Numbers As Economy Collapses

 

Deadly Microsoft Patent Application given to Newbie Examiner Jahed Ali

https://tinyurl.com/ycts74cy

PUBLIC ALERT: Microsoft just filed for a patent to tie your cellular activity to your approval to buy and sell with cryptocurrency – application assigned to a patent examining newbie with NO EXPERIENCE by British SERCO.


Send demands to your elected representatives, media, White House and Microsoft itself to stop this outrageously evil patent application.


Jahed Ali, the patent examiner assigned is a total newbie with NO HISTORY.


Abramson et al. (Published Mar. 26, 2020). CRYPTOCURRENCY SYSTEM USING BODY ACTIVITY, Assignee: Microsoft, App. No. 16/138,518, Pub. No. US 2020/0097951 A1. USPTO.


body activities

crypto system

ali jahed

ali grant rate

Abramson et al. (Published Mar. 26, 2020). CRYPTOCURRENCY SYSTEM USING BODY ACTIVITY, Assignee: Microsoft, App. No. 16/138,518, Pub. No. US 2020/0097951 A1. USPTO.

The British Wage War on the World

sedition thumbnail

.

Raw audio file: https://aim4truth.org/wp-content/uploads/2020/04/British-Wage-War-against-the-World.mp3

Make sure to read the details under the headline link below. Save this TRUTH HISTORY in your family records so that your children are never indoctrinated by evil British monarchs again.

David Sarnoff – RCA, NBC, Pilgrims Society, Imperial British terrorist

Demand full disclosure of the war being waged by the British Imperial Empire against humanity.

full disclosure

AIM Patriot and investigative sci-tech journalist Ramola D. at The Everyday Concerned Citizen sends us the links below. Get some eyeballs on this, especially our British friends. Features info on Wellcome Trust,WHO, SAGE, GAVI, CEPI, and Imperial College.

David Noakes, CEO, Immuno Biotech | It’s Bill Gates Who Has Locked Down the World

UK Column News – 15th April 2020: The Imperial College Bill Gates Connection

Are your eyes wide open…or are you still asleep? Make sure your information network knows about Tavistock programming and how it is used on a mass GLOBAL scale. The British Imperial Empire uses psychology and biology to terrorize the world so that the BATshit Queen and her evil Empire can take over the world. Please note that there are some comments in the video below that may or may not suit your spiritual inclinations.

.

coronavirus control

.

The world is jumping on the Let’s Sue China Train. OK with us. We will watch from the sidelines as it unfolds…but remember that the Queen is playing XI as the fool he is. Once we grab our reparations from China, let’s go after after the royal scum for their wealth. Any other country joining us or will America be the sole benefactors of the wealth of the British Imperial Empire when we strip the Privy Council and the royal trash for their crimes against humanity?

China Outraged After Largest German Newspaper Accuses Beijing Of “Exporting” Coronavirus Pandemic, Demands €149 Billion In Damages

pirbright patent

xi queen

.

Evil Bill Gates

gates evil

This evil eugenicist has been working for decades to find a way for citizens to be injected by his poisons. Has your child been harmed by his vaccine poisons? In the United States, you can’t sue him because long ago he set up special vaccine courts  – star chambers for the pharmaceutical industry, CDC, and Bill and Melinda Gates so that they can never be held responsible for the lifelong damages done to your children. If your doctor is still pushing untested vaccines on your family, they have been brainwashed in medical school by the very industry that financially supports medical schools – the pharmaceutical industry.

When are you going to see this for what it is? Humanity is being FARMED by the global controllersthe Pilgrims Society sits top of the apex that David Icke described in the video we posted. Membership in the Pilgrims Society includes the Queen and Privy Council members. No one who is a citizen in a Commonwealth Nation is legally permitted to research or speak about the “Queen’s business.” As good as their research is, Amazing Polly (from Canada) and David Icke (from the UK) will never be able to give  you details about the apex of the control pyramid without legal, personal repercussions. They will not be able to tell you that the Queen holds the controlling shares of the corporations that unleashed the deadly coronavirus on to the world. It is the Queen who controls Pirbright and Qinetiq and it is her propaganda arm called the BBC that pushes the fear porn to frighten the sheeple.

We did the research. You examined it. The corporate media is an enemy of the people. You have a patriotic responsibility to turn it off in your house and begin a campaign to get other people to do the same. This is a war for the minds of individuals in order to destroy humanity.

48 red borderAs David tells us, get off the couch and do something. This is a very important message for the influencers who read this blog.

The time has come to win the American Revolution against the British Empire.

We must win for the sake of our cousins in Britain who have been left defenseless, our patriot friends around the world who long for freedom, and for our future peace and prosperity here and around the world.

rush limbaugh

.

CoreyAnder posts:

People will now need to choose – was it all overblown by the media, or was handled expeditiously by Trump? Either way we win.

.

Coronavirus Fraud Shows Stupidity of Xi Jinping

The new man-made version of SARS (version 2), called Corona Virus ID 19, is only a “pandemic” because the Chinese let it spread to 190 nations before admitting they even knew it had been released in their country. The Chinese are so naïve that they don’t even know who released it. It was, of course, the “usual suspects” – the Queen of England (Privy Council) and her Pirbright/Merial virus-makers. The Brits have been using Africa, China, and many other countries for their experiments in biological warfare which creates the myth of “person zero”, or the one person who supposedly mixed human and animal viruses together – somehow.

Essentially, most pandemics or epidemics are from man-made customized viruses. This has been a major tool for invisible warfare since the time of Burroughs-Wellcome Drug company starting their experimentation with injecting viruses and diseases into unwitting subjects since 1902.

pirbright patent

The newest custom-man SARS virus that produced the hysteria and panic of the COVID-19 insanity is just another attempt at perfecting the yearly influenza deaths that the biowarfare department at Pirbright has been trying to do for decades. This new attempt is lame, but the response to the propaganda has been astoundingly effective that has caused the whole world to be locked down over a virus that is no more powerful than the common yearly flu. Don’t be fooled, this is a false flag attack by the Brits to continue their coup against Donald Trump – who the globalists see as the death of the nasty virus called “Globalism.”

If you take a look at the statistics below, you will see that it is self-evident that this COVID-19 is nothing to worry about, and certainly nothing to crash national economies over. It is a hoax. Another attempt of the British eugenicists to kill more people and depopulate the world. Don’t fall for the propaganda of this yellow journalism that has, once again, created a war from a tiny battle.

This is simply another attempted coup against Trump, the leader of the populist movement world-wide.

You will also find a list below of approved medical drugs and treatments for viruses that are often 100% effective at stopping a corona virus. These treatments are used effectively all over the world – accept in the USA. The CDC and NIH won’t let these treatments and drugs even be tested, let alone used. They don’t want to heal anyone.

Just look at the drug for Malaria, chloroquine sulphate, which also works to heal COVID-19 if used in conjunction with other drugs. The CDC and NIH have had 20 years to “START” their studies on this drug to help stop viruses – but they refuse. This drug alone could stop the CDC/NIH vaccine racket. This is indicative of the complete control “big pharma” has over American citizen’s bloodstream. Every day we get closer to a CDC martial law controlled country. The CDC is a private corporation that made 4.1 billion off of their privately owned 56 vaccine patents last year. Does anyone smell a rat? It is time to remove the corporate viruses from the CDC and NIH.

Coronavirus 19 Cases

Coronavirus Cases world-wide: 460,487

Deaths 20,831

Coronavirus Cases in the US: 65,652

Deaths: 931 

US Flu (Influenza) Deaths 

During the 2019-2020 U.S. Flu Season so far there have been:

23,000 – 59,000 flu deaths

38,000,000 – 54,000,000 flu illnesses

17,000,000 – 25,000,000 flu medical visits

390,000 – 710,000 flu hospitalizations

Pneumonia in the US in 2017

There were 2.56 million people who died from pneumonia in 2017 world-wide. Almost a third of all victims were children younger than 5 years, it is the leading cause of death for children under 5. There were 49,157 U.S. deaths in 2017.

1,300,000 hospitalizations in 2017

2,560,000 deaths world-wide in 2017

49,157 U.S. deaths in 2017

Biological Warfare

Wake up and realize that every fowl virus or illness known to man has been turned into a biological weapon. Just some of the diseases considered for or known to be used as a biological  weapon include anthrax, ebola, Marburg virus, plague, cholera, typhus, Rocky Mountain spotted fever, tularemia, brucellosis, Q fever, machupo, Coccidioides mycosis, Glanders, Melioidosis, Shigella, Psittacosis, Japanese B encephalitis, Rift Valley fever, yellow fever, and smallpox.

Successful Anti-Viral Drugs Forbidden by CDC & NIH

The CDC and NIH are lying to us. There are no known vaccines for viruses — they simply don’t exist and yet all of the CDC and NIH time and money is spent on creating vaccines. Both “big pharma” institutions (CDC/NIH) ignore that fact and don’t allow any research on drug treatments that have been shown effective against viruses. Any of the treatments below that have a drug name in parenthesis after its name is an approved treatment plan in many, many other nations, beside the CDC/NIH controlled United Stated of America.

Some of the most effective and promising anti-viral drugs:

Remdesivir, Oseltamivir (Tamiflu), Zanamivir (Relenza), Abacavir for HIV, Amprenavir (Agenerase) for HIV, Amantadine, Rimantadine, Galidesivir, Interferon, Reverse Transcriptase Inhibitor, Cidofovir, Combivir, Daclatasvir (Daklinza), Darunavir, Dolutegravir, Acyclovir (Aciclovir) for herpes/Chicken Pox, Atazanavir, Adefovir for Hepatitis B, Balavir, Baloxavir marboxil (Xofluza), Boceprevir (Victrelis), Amantadine for influenza, Doravirine (Pifeltro), Elvitegravir, Entecavir, Etravirine (Intelence), Famciclovir, Fosamprenavir, Ganciclovir (Cytovene), Ibalizumab (Trogarzo), Imunovir, Indinavir, Letermovir (Prevymis), Lopinavir, Nelfinavir, Nexavir, Norvir, Penciclovir, Peramivir (Rapivab), Raltegravir, Rilpivirine (Edurant), Ritonavir, Saquinavir, Simeprevir (Olysio), Sofosbuvir, Telaprevir, Trizivir, Telbivudine (Tyzeka), Tenofovir alafenamide, Tenofovir disoproxil, Tenofovir, Tipranavir, Valaciclovir (Valtrex), Valganciclovir, Zanamivir (Relenza)

Other Anti-Viral Treatments Hidden by the CDA & NIH 

Ampligen,  Arbidol, Atripla, Biktarvy, Cobicistat (Tybost), Delavirdine, Descovy, Didanosine, Docosanol, Ecoliever, Edoxudine, Efavirenz, Emtricitabine, Enfuvirtide, Fomivirsen, Foscarnet, Fosfonet, Ibacitabine, Idoxuridine, Imiquimod, Inosine, Interferon type I, Interferon type II, Interferon type III, Lamivudine, Loviride, Maraviroc, Methisazone, Moroxydine, Nevirapine, Nitazoxanide, Peginterferon alfa-2a, Peginterferon alfa-2b, Pleconaril, Podophyllotoxin, Pyramidine, Ribavirin, Rimantadine, Stavudine, Trifluridine, Tromantadine, Truvada, Vicriviroc, Vidarabine, Viramidine, Zalcitabine, Zidovudine

Influenza as Eugenics

The first influenza pandemic was recorded in 1580, and since then, influenza pandemics occurred every 10 to 30 years. 

Coronaviruses are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A new strain of coronavirus (SARS-CoV-2) causes Coronavirus disease 2019, or COVID-19. Common signs of infection include respiratory symptoms, fever, cough, shortness of breath, and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. 

Middle East Respiratory Syndrome (MERS-CoV) was transmitted from dromedary camels to humans.

Severe Acute Respiratory Syndrome (SARS-CoV) SARS-CoV was transmitted from civet cats to humans, was identified in 2003

Russian Flu (1889-1890) H3N8 and H2N2, began in May 1889 in Uzbekistan. By October, it had reached Tomsk and the Caucasus. It rapidly spread west and hit North America in December 1889, South America in February 1890, India in February 1890, and Australia in March 1890.

1,000,000 deaths

Spanish Flu (1918-1920) H1N1 pandemic lasted from March 1918 to October 1920. It started in US troops training at Camp FunstonKansas. By October 1918, it had spread to all continents, and eventually infected about one-third of the world’s population, 500 million people. In six months, some 50 million were dead. About 17 million died in India, 675,000 in the United States and 200,000 in the UK.

50,000,000 – 100,000,000 deaths

Asian Flu (1957–58) H2N2  avian influence virus first identified in China in late February 1957. It caused about 2 million deaths globally. The Asian flu spread to the United States by June 1957 and caused about 70,000 deaths in the US.

1,000,000 – 4,000,000 deaths

Hong Kong Flu (1968-69) H3N2  virus first detected in Hong Kong in early 1968 and spread to the United States later that year. This pandemic of 1968 and 1969 killed approximately one million people worldwide. It caused about 34,000 deaths in the United States.

1,000,000 deaths

Avian Flu (February 2004) H5N1 avian influenza virus was detected in birds in Vietnam, increasing fears of the emergence of new variant strains. In October 2005, Avian Flu was identified in Turkey, Russia, Mongolia, China, Romania, and Greece. By November 2007, cases had been identified across Europe.  However, by the end of October, only 59 people had died as a result of H5N1, which was atypical of previous influenza pandemics.

59 deaths

Swine Flu (2009-10) H1N1 virus first detected in Mexico in 2009 and spread to the United States later that year. This pandemic killed around half a million people worldwide. It caused about 12,000 deaths in the United States.

500,000 deaths

H1N1 Variant (2009) The variant had spread widely with cases reported in Canada, the US, New Zealand, the UK, France, Spain and Israel. H1N1 Variant reached pandemic proportions, with nearly 30,000 confirmed cases worldwide in 206 countries reporting over 503,536 laboratory confirmed cases.

6,250 deaths

Other Man-Made Deadly Viruses

Viral Hemorrhagic Fevers: Ebola, Lassa fever, Rift Valley fever, Marburg virus disease and Bolivian hemorrhagic fever are highly contagious and deadly diseases, with the theoretical potential to become pandemics.

Zika Virus (2015-16) began in 2015 with over 1.5 million cases across more than a dozen countries in the Americas. The World Health Organization warned that Zika had the potential to become an explosive global pandemic if the outbreak was not controlled.

Tuberculosis – One-quarter of the world’s current population has been infected with Mycobacterium tuberculosis, and new infections occur at a rate of one per second. About 5-10% of these latent infections will eventually progress to active disease, which, if left untreated, kills more than half of its victims. Annually, 8 million people become ill with tuberculosis, and 2 million people die from the disease worldwide.  In the 19th century, tuberculosis killed an estimated one-quarter of the adult population of Europe; by 1918, one in six deaths in France were still caused by tuberculosis. During the 20th century, tuberculosis killed approximately 100 million people.

8,000,000 deaths per year

HIV/AIDS (1981) Appears early with flu-like symptoms, then enlarged lymph nodes, fever, weight loss, infections, and tumors. Near normal life expectancy after contraction with treatment — 11 years life expectancy without treatment. There ae 37.9 million people living with HIV with 770,000 deaths in 2018. HIV originated in west-central Africa during the late 19th or early 20th century.

32,000,000 deaths 

Now, let’s start looking at the real face behind the coronavirus fraud.

queen coronavirus

Nanotechnology Weaponized to Deliver Viruses

Change one word (drug to [Corona]virus) in this paper and this delivery system becomes a bioweapon.

Gangi, Mirzaei, Dalirandeh. (Jul. 05, 2017). Molecular origin of drug release by water boiling inside carbon nanotubes from reactive molecular dynamics simulation and DFT perspectives. Sci Rep 7, 4669.

molecules

https://doi.org/10.1038/s41598-017-04981-2

https://www.fbcoverup.com/docs/library/2017-07-05-Molecular-origin-of-drug-release-by-water-boiling-inside-carbon-nanotubes-from-reactive-molecular-dynamics-simulation-and-DFT-perspectives-by-Gangi-Mirzaei-Dalirandeh-Sci-Rep-7-4669-Jul-05-2017.pdf

charles lieber afi

Harvard Pilgrims Society professor-surrogate exploited like Zuckerberg and the other Silicon Valley stooges to weaponize nanotechnology to deliver viruses and other weaponized pathogens via 5G (boil the water in the nanotube with 5G milliwave-lengths and it will release its toxic payload, see above); is this what happened in Wuhan, China?

Charles M. Lieber, ed. (Feb. 05, 2008). Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. PNAS (Proceedings of the National Academy of Sciences US).

molecules 2

Charles [M.] Lieber. (Compiled Mar. 20, 2020). Patent Inventor search IN/”Lieber, Charles”. U.S. Patent Office.

charles lieber 1

Lieber’s Harvard list of nanotech conspirator-members:

Charles M. Lieber. (Accessed Mar. 19, 2020). Biography, Principal Investigator. Chemistry and Chemical Biology Department, School of Engineering and Applied Sciences. Harvard University.

https://www.fbcoverup.com/docs/library/2020-03-19-Charles-M-Lieber-Bio-Princ-Invgtr-Chem-and-Chemical-Biology-Dept-School-of-Eng-and-App-Scs-Harvard-accessed-Mar-19-2020.pdf

charles lieber 2